CJC-1295 and Ipamorelin FDA Status 2026: Approval, Compounding Rules, and Safety Risks

Introduction

CJC-1295 and ipamorelin are peptides discussed in research on growth-hormone signaling. They are also frequently mentioned together in online wellness and longevity content. However, scientific interest and commercial promotion should not be confused with regulatory approval.

As of October 23, 2026, CJC-1295, ipamorelin, and the CJC-1295/ipamorelin combination are not FDA-approved human therapeutic drug products. FDA has also raised safety and quality concerns about these substances in its evaluations of bulk ingredients proposed for pharmacy compounding.

Their regulatory status involves three distinct questions:

1. FDA approval: Has FDA approved a finished drug for a specific medical indication?

2. Compounding eligibility: Does a substance meet the legal requirements for use in a compounded drug under the applicable federal framework?

3. Research-use status: Does a product’s labeling identify it for laboratory research rather than human treatment?

These questions have different answers and should not be treated as interchangeable. A peptide’s appearance in research, its availability through a commercial seller, or its use in a compounded preparation does not establish that FDA has approved it.

Key Takeaways

• Neither peptide is FDA-approved: CJC-1295 and ipamorelin do not have FDA-approved human therapeutic indications in the regulatory materials reviewed.

• The combination is not approved: Combining two unapproved substances does not create an FDA-approved medicine.

• FDA has identified safety concerns: CJC-1295-related substances raise concerns involving limited clinical evidence, peptide impurities, characterization, and reported adverse events. FDA has identified separate concerns involving ipamorelin acetate.

• 503A and 503B are different frameworks: Their lists and interim policies should not be combined into a single general statement about compounding.

• Category removal is not approval: Withdrawal of a nomination can lead to removal from an interim category without adding the substance to the relevant Bulks List.

• Research-use labeling is not evidence of human safety: A research label does not establish that a substance is safe or effective for medical treatment.

1. Is CJC-1295 and Ipamorelin FDA-Approved in 2026?

No. Neither CJC-1295 nor ipamorelin is an FDA-approved human therapeutic drug, and no FDA-approved finished product containing the CJC-1295/ipamorelin combination is identified in the sources reviewed for this article.

FDA approval applies to a particular drug product and its approved conditions of use. Evidence that a compound affects a biological pathway is not sufficient on its own to establish clinical effectiveness or obtain approval.

The distinction is particularly important for peptides discussed in longevity and wellness marketing. Preliminary clinical research, proposed mechanisms, and commercial claims do not replace the evidence and regulatory review required for an approved medicine.

For current regulatory information, consult the FDA’s drug-compounding resources.

2. CJC-1295 FDA Status: What Did the Agency Review?

FDA evaluated five CJC-1295-related bulk drug substances in preparation for the December 4, 2024, Pharmacy Compounding Advisory Committee (PCAC) meeting.

The substances were:

• CJC-1295 free base

• CJC-1295 acetate

• CJC-1295 with drug affinity complex (DAC), free base

• CJC-1295 DAC acetate

• CJC-1295 DAC trifluoroacetate (TFA)

The substances were considered in the context of potential inclusion on the list of bulk drug substances that may be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act.

FDA’s briefing explained that the nomination materials contained inconsistent information about the intended substances. Although the nominations were withdrawn, FDA proceeded with its own evaluation of the five forms.

Limited clinical evidence

FDA described the available clinical data as limited. Evidence from early studies does not automatically demonstrate that a substance is safe and effective for a specific medical indication.

Peptide characterization and impurities

FDA discussed issues relevant to peptides, including potential immunogenicity, self-association, aggregation, peptide-related impurities, and difficulties in characterization.

These concerns matter because a substance’s identity, composition, and quality must be adequately understood when assessing its suitability for use in a compounded drug.

Reported adverse events

FDA’s safety materials identify serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reactions. The PCAC briefing also discussed findings from clinical studies involving CJC-1295 DAC, including injection-site reactions and other reported adverse effects.

These findings should be interpreted in context. They represent safety signals and evidence considered by FDA; they should not be presented as proof that every exposure causes the same outcome.

No FDA-approved drug component

FDA’s December 2024 briefing stated that none of the five evaluated CJC-1295-related substances was a component of an FDA-approved drug.

Regulatory takeaway: FDA’s review identified unresolved safety, characterization, and evidence issues. The review did not confer approval on CJC-1295 or its related forms.

Official reference: FDA’s December 2024 CJC-1295 briefing document.

3. CJC-1295 Category 2 Status: Why Removal Did Not Mean Approval

FDA’s September 2024 update stated that CJC-1295-related nominations had been withdrawn and that CJC-1295 was removed from Category 2 under the interim 503A policy.

This administrative change is often misunderstood.

Removal from Category 2 after a withdrawn nomination does not mean FDA approved the substance or added it to the 503A Bulks List.

The subsequent December 2024 PCAC review considered five CJC-1295-related substances for potential inclusion on that list. The committee’s recommendation was adverse to inclusion of the substances under consideration.

The regulatory steps are different:

• Nomination withdrawal: A nominator withdraws a request for consideration.

• Category classification: FDA applies its interim compounding policy to a nominated substance.

• PCAC recommendation: An advisory committee provides its recommendation on a regulatory question.

• 503A Bulks List inclusion: FDA determines whether a bulk drug substance is included on the relevant list.

• Drug approval: FDA approves a finished drug product for a specific use through the applicable approval process.

One step should not be represented as if it automatically completes another.

The distinction is important for accurate reporting because the absence of a substance from Category 2 does not independently establish that it is eligible for routine compounding.

Official references:

• FDA’s September 2024 503A categories update

• FDA’s December 2024 PCAC meeting materials

4. Ipamorelin FDA Status: Safety and Evidence Concerns

FDA has separately evaluated ipamorelin-related bulk drug substances, including ipamorelin free base and ipamorelin acetate.

Its public safety materials identify concerns involving the characterization and quality of ipamorelin acetate and limitations in the available safety information.

Potential immunogenicity

FDA states that compounded drugs containing ipamorelin acetate may pose immunogenicity risks for certain routes of administration. Potential aggregation and peptide-related impurities are among the factors identified by the agency.

Immunogenicity refers to a substance’s ability to provoke an immune response. The potential risk depends on the substance and product characteristics; it should not be interpreted as proof that every exposure will produce an immune reaction.

Challenges in substance characterization

FDA noted that ipamorelin acetate contains unnatural amino acids, adding complexity to peptide characterization.

This is relevant to evaluating the identity and quality of a bulk substance proposed for use in a compounded medicine.

Limited information for certain injectable routes

FDA stated that it had not identified sufficient safety-related information for certain other injectable routes of administration. Consequently, the agency lacked sufficient information to determine whether ipamorelin acetate would cause harm if administered to humans through those routes.

An absence of adequate information does not prove that harm will occur. It also does not establish that the substance is safe.

Serious adverse events in an intravenous study

FDA reviewed a study of ipamorelin administered intravenously for improving gastric motility. Serious adverse events, including deaths, were reported among study participants.

FDA noted that it was unclear whether the deaths were related to ipamorelin. A responsible summary should preserve that qualification rather than asserting that the compound caused the deaths.

Official reference: FDA’s October 2024 ipamorelin briefing materials.

5. Ipamorelin Category 2 Status: 503A vs. 503B

The distinction between 503A and 503B compounding is central to understanding ipamorelin’s regulatory status.

FDA’s September 2024 503A update stated that ipamorelin acetate had been removed from Category 2 after its nomination was withdrawn. FDA nevertheless proceeded with its evaluation of ipamorelin-related substances for potential inclusion on the 503A Bulks List.

Separately, FDA’s significant-safety-risk materials identify ipamorelin acetate under Category 2 of the interim 503B policy.

The table summarizes the distinction between nomination history and the separate 503B safety classification. It should not be read as a substitute for the current FDA lists or a legal determination about a particular product.

Under FDA’s interim 503B policy, Category 2 identifies substances for which FDA has identified significant safety risks and does not intend to apply the Category 1 interim enforcement policy.

Official references:

• FDA: Bulk drug substances that may present significant safety risks

• FDA: Bulk drug substances used in compounding under section 503A

• FDA: Bulk drug substances used in compounding under section 503B

6. Can CJC-1295 and Ipamorelin Be Compounded?

Compounding eligibility is separate from FDA approval. It depends on the applicable statutory framework, the substance involved, and the circumstances of the preparation.

Under section 503A, bulk drug substances generally must meet the applicable legal conditions, including the relevant requirements concerning the 503A Bulks List or other permitted basis for compounding. The withdrawal of a nomination does not itself satisfy those requirements.

Under section 503B, outsourcing facilities operate under a different statutory framework and FDA interim policies. Ipamorelin acetate’s Category 2 listing indicates that FDA has identified significant safety concerns and does not intend to extend the Category 1 interim enforcement policy to it.

For these reasons, it is inaccurate to claim that CJC-1295 or ipamorelin became automatically eligible for compounding merely because a nomination was withdrawn or a category entry changed.

It is also important not to treat the existence of a compounded product as proof that it is FDA-approved. FDA explains that compounded drugs are not reviewed and approved in the same way as approved drug products.

Reference: FDA: Understanding the risks of compounded drugs.

7. Has the CJC-1295 and Ipamorelin Combination Been Proven Effective?

The evidence for each peptide must be distinguished from evidence for the combination.

Research involving a single compound cannot automatically establish the safety or effectiveness of a blend containing two compounds. The combination would need appropriate evidence addressing the product and the outcomes being claimed.

The secondary sources reviewed for this article do not identify a published controlled human trial establishing the combination’s effectiveness for claims such as fat loss, muscle gain, recovery, sleep improvement, skin rejuvenation, or longevity.

That is a narrower and more defensible statement than claiming that no research of any kind exists. It also does not mean that every proposed biological effect has been definitively disproven; rather, the available evidence cited here does not establish those therapeutic benefits for the combination.

FDA’s compounding reviews focus on the nominated substances and proposed uses considered by the agency. They should not be interpreted as proof of clinical effectiveness for unrelated wellness claims.

8. CJC-1295 DAC vs. No-DAC: Why Naming Matters

The terms “CJC-1295 DAC” and “CJC-1295 no-DAC” are used to distinguish forms described in research and commercial materials.

DAC refers to a drug-affinity-complex modification associated with albumin binding. “No-DAC” is commonly used in research contexts for a different form, often referred to as modified GRF 1-29.

FDA’s December 2024 briefing distinguished multiple CJC-1295-related substances, including free-base, acetate, DAC, and TFA forms. The agency also described inconsistencies in the original nomination information.

This distinction matters because different chemical substances should not be assumed to be identical simply because similar names appear on a label or document.

The terminology also illustrates why regulatory statements should identify the specific substance evaluated rather than using “CJC-1295” as if every related form necessarily had identical characteristics.

9. How Does Tesamorelin Compare?

Tesamorelin is an example of a medicine with a specific FDA-approved indication in the growth-hormone-related field.

Tesamorelin is approved as Egrifta for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its approval applies to the product and indication described in its prescribing information.

That approval does not extend to CJC-1295, ipamorelin, or their combination. It also does not establish approval for general anti-aging, bodybuilding, or every condition associated with growth hormone.

The regulatory lesson is straightforward: medicines with related biological pathways are not interchangeable, and each product’s approval status must be assessed independently.

Frequently Asked Questions

Is CJC-1295 and ipamorelin FDA-approved in 2026?

No. Neither peptide is an FDA-approved human therapeutic drug, and the combination is not an FDA-approved finished drug product.

Is CJC-1295 on the 503A Bulks List?

The FDA materials reviewed do not identify the evaluated CJC-1295-related substances as included on the 503A Bulks List. Their nominations were withdrawn, and FDA separately evaluated five related substances. Withdrawal did not itself establish eligibility for compounding.

Is ipamorelin on the 503A Bulks List?

The FDA materials reviewed describe the withdrawal of the ipamorelin-related nominations and FDA’s subsequent evaluation of ipamorelin free base and acetate. A withdrawn nomination is not the same as inclusion on the 503A Bulks List.

Is ipamorelin acetate still listed under 503B Category 2?

FDA’s significant-safety-risk materials identify ipamorelin acetate under Category 2 of the interim 503B policy. This classification concerns compounding policy and safety risks; it is not a drug approval.

Does removal from Category 2 mean a peptide is approved?

No. Removal after a withdrawn nomination does not establish FDA approval or automatic eligibility for compounding. The relevant Bulks List and applicable legal requirements must be considered separately.

Does a compounded CJC-1295/ipamorelin product have FDA approval?

No. A compounded preparation is not FDA-approved simply because a pharmacy or clinic offers it. Compounding eligibility and finished-drug approval are separate regulatory questions.

What safety concerns has FDA identified?

For CJC-1295-related substances, FDA has identified limited clinical evidence, characterization challenges, peptide-related impurity and aggregation concerns, and reported serious adverse events. For ipamorelin acetate, FDA has identified potential immunogenicity, peptide-related impurities, characterization challenges, and insufficient safety information for certain routes. FDA also reviewed a study in which serious adverse events, including deaths, occurred among participants receiving intravenous ipamorelin; the agency stated that it was unclear whether the deaths were related to the drug.

Is the combination proven for anti-aging or body-composition benefits?

The sources reviewed here do not establish the combination’s effectiveness for anti-aging, fat loss, muscle gain, recovery, sleep, or longevity. Claims of benefit should not be presented as established clinical outcomes without appropriate evidence.

Conclusion

The 2026 FDA status of CJC-1295 and ipamorelin requires a clear distinction between drug approval, compounding policy, and research-use labeling.

Neither peptide nor their combined product is an FDA-approved human therapeutic drug. FDA’s evaluations have identified concerns involving the available clinical evidence, peptide characterization, impurities, and potential safety risks. Ipamorelin acetate also remains identified in FDA’s 503B Category 2 safety materials.

The withdrawal of nominations and removal from a compounding-policy category should not be presented as approval or automatic permission to compound. Likewise, commercial availability and research-use labeling do not establish that a product is safe or effective for human treatment.

For accurate reporting, use the latest FDA listings and briefing documents, identify the relevant substance and compounding pathway, and avoid treating an advisory recommendation or administrative update as a final drug approval.

Official FDA References

1. FDA: Certain bulk drug substances that may present significant safety risks

2. FDA: December 2024 CJC-1295 briefing document

3. FDA: October 2024 PCAC meeting materials

4. FDA: September 2024 503A categories update

5. FDA: Bulk drug substances used in compounding under section 503A

6. FDA: Bulk drug substances used in compounding under section 503B

7. FDA: Understanding the risks of compounded drugs

Disclaimer: This article is for educational purposes only and is not medical or legal advice. FDA policies and regulatory classifications can change. Verify the latest official materials before relying on time-sensitive regulatory statements.